KAT6A and ovarian carcinoma: In addition to leukemia, MOZ have been found abnormally expressed in other cancer types such as glioblastoma (Lv et al., 2017), medulloblastoma (Northcott et al., 2009), breast cancer (Yu et al., 2017), colorectal cancer (Mohammadi et al., 2019; Xie et al., 2020), uterine cervix cancer (Zack et al., 2013; Jiang et al., 2020), ovarian cancer (Zack et al., 2013; Liu et al., 2021), lung cancer, bladder cancer and several adenocarcinomas (Jiang et al., 2020).